Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Upregulation of alveolar fluid clearance is not sufficient for Na<sup>+</sup>,K<sup>+</sup>-ATPase β subunit-mediated gene therapy of LPS-induced acute lung injury in mice.

Scientific reports·2026
Same author

Anticodon-edited transfer RNAs (ACE-tRNAs) encoded as therapeutic nonviral minimal DNA vectors.

Nucleic acids research·2026
Same author

Subnuclear organization and mislocalization of plasmids reduce transgene expression.

Molecular therapy. Nucleic acids·2025
Same author

Anticodon Edited Transfer RNAs (ACE-tRNAs) Encoded as Therapeutic Nonviral Minimal DNA Vectors.

bioRxiv : the preprint server for biology·2025
Same author

Electroporation- and Liposome-Mediated Co-Transfection of Single and Multiple Plasmids.

Pharmaceutics·2025
Same author

Ki-67 promotes inflammatory signaling governing neutrophil recruitment during respiratory infections.

EMBO molecular medicine·2025
Same journal

Critical Care and Contagion: Evolving Frontiers of Infectious Diseases in the Modern Intensive Care Unit.

Critical care clinics·2026
Same journal

Advances and Challenges in Sepsis Care in Low-Resource Settings.

Critical care clinics·2026
Same journal

The Respiratory Triple Pandemic in the Intensive Care Unit: Epidemiology, Clinical Features and Management of COVID-19, Influenza and Respiratory Syncytial Virus.

Critical care clinics·2026
Same journal

Antibiotic Stewardship for the Intensivist.

Critical care clinics·2026
Same journal

Infection Prevention and Control in the Intensive Care Unit.

Critical care clinics·2026
Same journal

Antibiotic Considerations in the Critically Ill: Empiric Choices and Dosing.

Critical care clinics·2026
See all related articles

Related Experiment Video

Updated: May 31, 2026

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants
09:20

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants

Published on: October 18, 2022

Gene therapy for ALI/ARDS.

Xin Lin1, David A Dean

  • 1Department of Pediatrics, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA.

Critical Care Clinics
|July 12, 2011
PubMed
Summary
This summary is machine-generated.

Gene therapy offers a promising approach for treating acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Recent advancements in viral and nonviral gene transfer systems enhance its potential for clinical application in pulmonary diseases.

More Related Videos

A Validatable Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno-Associated Viral Vectors in Bioshedding Studies of Tears
07:43

A Validatable Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno-Associated Viral Vectors in Bioshedding Studies of Tears

Published on: July 14, 2023

Related Experiment Videos

Last Updated: May 31, 2026

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants
09:20

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants

Published on: October 18, 2022

A Validatable Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno-Associated Viral Vectors in Bioshedding Studies of Tears
07:43

A Validatable Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno-Associated Viral Vectors in Bioshedding Studies of Tears

Published on: July 14, 2023

Area of Science:

  • Pulmonary Medicine
  • Molecular Therapy
  • Biotechnology

Background:

  • Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are critical conditions characterized by acute respiratory failure.
  • These syndromes are linked to a variety of underlying disorders, necessitating innovative therapeutic strategies.
  • Current treatments for ALI/ARDS have limitations, driving the search for novel interventions.

Purpose of the Study:

  • To review recent advancements in gene therapy for treating lung diseases associated with ALI/ARDS.
  • To discuss the development and efficacy of viral and nonviral gene transfer systems for pulmonary applications.
  • To evaluate the current status and future potential of gene therapy in managing ALI/ARDS-associated conditions.

Main Methods:

  • Literature review of recent studies on gene therapy for ALI/ARDS.
  • Analysis of viral and nonviral gene delivery methods for lung applications.
  • Assessment of current research and clinical trial data related to gene therapy in pulmonary diseases.

Main Results:

  • Significant progress has been made in developing more efficient viral and nonviral gene transfer vectors.
  • Various gene therapy approaches are being explored for their potential to treat ALI/ARDS.
  • The efficacy and safety profiles of different gene delivery systems are under continuous investigation.

Conclusions:

  • Gene therapy represents a promising therapeutic strategy for ALI/ARDS and related pulmonary diseases.
  • Continued development of advanced gene therapy vectors is crucial for successful clinical translation.
  • Gene therapy holds significant potential for improving patient outcomes in ALI/ARDS.